Health Care

Lab-grown meat is raising new questions for religious leaders, including Rabbi Yuval Cherlow, who is considering whether meat grown from animal cells in a petri dish will fit into the kosher tradition.

The Food and Drug Administration gave a year-end gift to the generic drug industry by backing off a proposal that would have opened up generic companies to possible product-liability lawsuits over drug safety.

When a Chinese scientist claimed last month that he created the first genetically modified babies, scientists around the world were stunned and alarmed. Now, scientists who examined the very limited available data from the experiments are questioning whether the gene edits the scientist claimed he made were even successful.

The price of insulin has skyrocketed over the last few decades, making it increasingly difficult for diabetics to afford. WSJ’s Jason Bellini takes a look at some of the unconventional steps Americans are taking to access the lifesaving drug.

Amazon.com has begun to sell software that mines patient medical records for information doctors and hospitals could use to improve treatment and cut costs, the latest move by a big technology company into the health-care industry.

The Food and Drug Administration is significantly revamping the way it clears most medical devices for U.S. marketing, planning to rely far less on comparisons with much older products already on the market.

A patient’s family history of cardiovascular disease and in some cases a heart scan are among the factors that physicians should consider before prescribing drugs to lower cholesterol, according to new clinical guidelines.

North Carolina wants to reshape how it pays for its workers’ health care—and save hundreds of millions of dollars—by scrapping the secret negotiations typically used to set rates with doctors and hospitals.

New research found no benefit from two antipsychotic drugs widely used by hospitals to treat delirium in critically ill patients, the latest study to call into question a common but unproven medical practice.

Private-equity firm General Atlantic has agreed to invest $200 million in a startup that aims to manage independent cancer-treatment clinics, the latest sign investors see opportunity in the health-services sector.

A new kind of drugmaker is emerging to meet demand for lower-priced medicines by custom-making drugs, sparking pushback from federal health regulators and legal challenges from traditional pharmaceutical companies.